- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Placebo, Selonsertib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 7,852
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine
- Interventions
- Ubrogepant 100 mg, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Cigarette Smoking
- Interventions
- Ask-Advise-Refer, Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release, Nicotine lozenge
- Behavioral · Drug
- Lead sponsor
- Sandra Japuntich
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
- Interventions
- Treatment with CD200AR-L
- Drug
- Lead sponsor
- OX2 Therapeutics
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 415
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- STRO-002
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
- Interventions
- Unmanipulated UCB, SR-1 UCB
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cerebrospinal Fluid Leak
- Interventions
- FS VH S/D 500 s-apr, DuraSeal Dural Sealant
- Drug · Device
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Cystic Fibrosis
- Interventions
- ELX/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
- Conditions
- ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
- Interventions
- Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
- Conditions
- Lymphoma, Nonneoplastic Condition
- Interventions
- bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 423
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- DNA ploidy analysis, comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
- Genetic
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Downey, California • Loma Linda, California + 48 more
- Conditions
- Lymphoma
- Interventions
- Simvastatin, Dexamethasone
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cancer
- Interventions
- Internet-based pain coping skills program
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 149
- States / cities
- Fort Smith, Arkansas • Antioch, California • Dublin, California + 118 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 12 more
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 58
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 46 more
- Conditions
- Smoking, Tobacco Use
- Interventions
- Ventilated cigarettes only, Unventilated cigarettes only, Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems, Access to Experimental Marketplace: Unventilated cigarettes + ANDS
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Columbus, Ohio
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- efgartigimod PH20 SC in stage B, placebo in stage B
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 9 Years
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2012
- U.S. locations
- 179
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more
- Conditions
- Basal Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 80
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 69 more
- Conditions
- Squamous Cell Carcinoma, Laryngeal Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Uterine Cervical Dysplasia
- Interventions
- Amolimogene, Placebo
- Drug · Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 13 Years to 25 Years · Female only
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Downey, California • Duarte, California + 90 more
- Conditions
- Anemia of Chronic Disease
- Interventions
- FMX-8
- Drug
- Lead sponsor
- FerruMax Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Arvada, Colorado • Minneapolis, Minnesota